Direct investigation of G Medical Innovations (NASDAQ:GMVD) and Stryker (NYSE:SYK)

Stryker (NYSE:SYK – Get Rating) and G Medical Innovations (NASDAQ:GMVD – Get Rating) are both medical companies, but which is the better stock? We’ll compare the two companies based on their risk strength, dividends, valuation, institutional ownership, profitability, earnings, and analyst recommendations.
Analyst Notes
This is a breakdown of recent ratings and recommendations for Stryker and G Medical Innovations, as provided by MarketBeat.
Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
stryker | 0 | 8 | 12 | 0 | 2.60 |
G Medical innovations | 0 | 0 | 0 | 0 | N / A |
Stryker currently has a consensus target price of $270.53, indicating a potential upside of 35.66%. Given Stryker’s possible higher upside, equity research analysts clearly believe that Stryker is more favorable than G Medical Innovations.
Valuation and benefits
This chart compares the gross revenue, earnings per share (EPS), and valuation of Stryker and G Medical Innovations.
Gross revenue | Price/sales ratio | Net revenue | Earnings per share | Price/earnings ratio | |
stryker | $17.11 billion | 4.41 | $1.99 billion | $5.26 | 37.91 |
G Medical innovations | N / A | N / A | N / A | N / A | N / A |
Stryker has higher revenues and profits than G Medical Innovations.
Insider and Institutional Ownership
74.5% of Stryker shares are held by institutional investors. 6.7% of Stryker shares are held by insiders. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock will outperform the market over the long term.
Profitability
This table compares the net margins, return on equity and return on assets of Stryker and G Medical Innovations.
Net margins | Return on equity | return on assets | |
stryker | 11.56% | 24.09% | 10.07% |
G Medical innovations | N / A | N / A | N / A |
Summary
Stryker beats G Medical Innovations on 8 of the 8 factors compared between the two stocks.
About Stryker
(Get an evaluation)
Stryker Corporation operates as a medical technology company. The Company operates through two segments, MedSurg and Neurotechnology, and Orthopedics and Spine. The Orthopedics and Spine segment provides implants for use in hip and knee replacements, as well as trauma and extremity surgeries. This segment also offers spinal implant products including cervical, thoracolumbar and interbody systems that are used in spinal injuries, deformities and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communication systems, patient handling, emergency medical equipment and critical care disposables, reprocessed and remanufactured medical devices and medical devices. ‘other medical device products used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for surgical procedures based on the brain and the open skull; orthobiology and biosurgery products, such as synthetic bone grafts and spinal augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic strokes; and craniomaxillofacial implant products, including cranial, maxillofacial and chest wall devices, as well as dural substitutes and sealants. The company sells its products to physicians, hospitals and other healthcare facilities through company-owned subsidiaries and branches, as well as to third-party resellers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
About G Medical Innovations
(Get an evaluation)
G Medical Innovations Holdings Ltd, together with its subsidiaries, an early-stage healthcare company, engages in the development of next-generation mobile health and telemedicine solutions in the United States, China and Israel. The Company’s products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical-grade reporting standards; and Extended Holter Patch System, a patient-worn multi-channel biosensor that captures electrocardiogram data continuously for up to 14 days. It is also developing the Wireless Vital Signs Monitoring System, a solution that enables continuous real-time monitoring of vital signs and biometrics. Additionally, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.
Get news and reviews for Stryker Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Stryker and related companies with MarketBeat.com’s FREE daily newsletter.